AbbVie (ABBV) Other Non-Current Liabilities (2012 - 2026)
AbbVie (ABBV) posted quarterly Other Non-Current Liabilities of $34.1 billion for Q1 2026, up 50.18% year-over-year from $22.7 billion in Q1 2025, and up 4.73% quarter-over-quarter from $32.6 billion in Q4 2025.
AbbVie (ABBV) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Other Non-Current Liabilities for 15 consecutive years, with $34.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 50.18% year-over-year to $34.1 billion; the TTM figure through Mar 2026 stood at $34.1 billion (up 50.18% YoY), while the FY2025 annual figure was $32.6 billion, up 50.32% from the prior year.
- Other Non-Current Liabilities advanced to $34.1 billion in Q1 2026 per ABBV's latest filing, from $32.6 billion in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $34.1 billion in Q1 2026 and bottomed at $13.8 billion in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $22.0 billion across 5 years, with a median of $20.2 billion in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities decreased 2.43% — and 2025, when it jumped 51.49%.
- AbbVie's Other Non-Current Liabilities stood at $16.4 billion in 2022, then gained by 21.4% to $19.9 billion in 2023, then climbed by 8.93% to $21.7 billion in 2024, then surged by 50.32% to $32.6 billion in 2025, then advanced by 4.73% to $34.1 billion in 2026.
- Business Quant data shows ABBV's Other Non-Current Liabilities at $34.1 billion in Q1 2026, $32.6 billion in Q4 2025, and $31.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.51 Bn | 632.75 Bn | 17.26 Bn |
| 2 | AbbVie | 470.67 Bn | 464.10 Bn | 12.70 Bn |
| 3 | Merck | 378.00 Bn | 370.86 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.24 Bn | 295.55 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.85 Bn | 252.95 Bn | 12.86 Bn |
| 6 | Amgen | 236.64 Bn | 222.65 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 182.27 Bn | 179.09 Bn | 6.22 Bn |
| 8 | Pfizer | 159.46 Bn | 147.76 Bn | 10.94 Bn |
| 9 | Gsk | 106.20 Bn | 102.03 Bn | 8.24 Bn |
| 10 | Sanofi | 55.06 Bn | 47.68 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.60 Bn |
| Mar 31, 2026 | 34.11 Bn |
| Dec 31, 2025 | 32.57 Bn |
| Sep 30, 2025 | 31.66 Bn |
| Jun 30, 2025 | 32.04 Bn |
| Mar 31, 2025 | 22.71 Bn |
| Dec 31, 2024 | 21.67 Bn |
| Sep 30, 2024 | 21.93 Bn |
| Jun 30, 2024 | 21.15 Bn |
| Mar 31, 2024 | 20.16 Bn |
| Dec 31, 2023 | 19.89 Bn |
| Sep 30, 2023 | 18.67 Bn |
| Jun 30, 2023 | 19.15 Bn |
| Mar 31, 2023 | 17.93 Bn |
| Dec 31, 2022 | 16.38 Bn |
| Sep 30, 2022 | 14.56 Bn |
| Jun 30, 2022 | 15.18 Bn |
| Mar 31, 2022 | 13.82 Bn |
| Dec 31, 2021 | 14.89 Bn |
| Sep 30, 2021 | 14.92 Bn |